| Literature DB >> 33840923 |
Rupali Patnaik1, Afzal Azim1, Prabhaker Mishra2.
Abstract
Sepsis is a life-threatening condition with dysregulated host response to infection. It is a major determinant of mortality in the intensive care unit (ICU). Procalcitonin (PCT) is widely investigated for prognosis in patients with sepsis. Most of the studies have cited that elevated PCT concentrations and PCT non-clearance are associated with poor outcomes in patients with sepsis and some studies have cited as having no additional benefit. Most of the studies have evaluated single PCT measurement and correlated with prognosis and outcome in septic patients. Limited literature is there about serial PCT levels and its impact on the outcome of patients with sepsis. We searched literature through PubMed, Embase, Web of Knowledge, and the Cochrane Library from 2007 to 2017 and present a systematic review and meta-analysis of studies evaluating the utility of serial measurement of PCT for prognosis in critically ill patients. Articles that assessed PCT non-clearance as a marker of mortality data were included. The primary objective of this meta-analysis was to pool the results of all the available studies on serial PCT non-clearance as a mortality predictor and formulate overall area under receiver operating curve (AUROC). To find out the overall proportion of mortality in PCT non-clearance was our secondary objective. To detect the mortality using PCT non-clearance, ROC curve analysis was done. Area under curve (AUC) of the studies was varying between 0.52 and 0.86. Overall AUC was observed 0.711 (95% confidence interval (CI): 0.662-0.760) under fixed effect model and 0.708 (95% CI: 0.648-0.769) under random effect model. There was moderate variation among the studies, i.e., I2 50.80% (95% CI: 0.00-80.42%). The overall proportion of mortality was 37.54% with much heterogeneity (I2 88.24%) among the studies. PCT non-clearance is a fair predictor of mortality. Further studies are needed to define optimal cut off point for PCT non-clearance in ICU patients with sepsis. Copyright:Entities:
Keywords: Procalcitonin; sepsis; septic shock
Year: 2021 PMID: 33840923 PMCID: PMC8022053 DOI: 10.4103/joacp.JOACP_388_19
Source DB: PubMed Journal: J Anaesthesiol Clin Pharmacol ISSN: 0970-9185
Characteristic of studies showing sensitivity and specificity of PCT non-clearance as a mortality predictor in ICU patients with sepsis and its severity
| Author | Year | Place | Study design | Clinical setting | Follow up | PCT assay | PCT non-clearance | Sample size | Overall mortality | Severity of sepsis | SEN % | SPE % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karlsson[28] | 2010 | Finland | Prospective | ICU | In hospital mortality | Cobas PCT | PCT ↓ <50% in 72 h | 242 | 62 (25.6) | Severe sepsis | 88.7 | 27.8 |
| Guan[29] | 2011 | China | Prospective | ICU | 28 day mortality | Lumitest PCT | PCT ↓ <25% in 5 days | 37 | 12 (32.4) | Sepsis, sev sepsis, septic shock | 100 | 100 |
| Tschaikowsky[30] | 2011 | Germany | Prospective | SICU | 28 day mortality | KRYPTOR-PCT | PCT ↓ <50% in 7 days | 64 | 21 (32.8) | Severe sepsi, septic shock | 35.3 | 97.1 |
| Ruiz-Rodriguez[31] | 2012 | Spain | Prospective | ICU | ICU mortality | Lumitest PCT | PCT ↓ <50% in 48 h | 27 | 18 (66.7) | Septic shock | 89 | 72 |
| Suberviola[32] | 2012 | Spain | Prospective | ICU | In hospital mortality | KRYPTOR-PCT | PCT ↓ <70% in 72 h | 88 | 21 (23.9) | Septic shock | 52.6 | 94.2 |
| Schuetz (Derivation cohort)[33a] | 2013 | USA | Prospective | ICU | ICU mortality | VIDAS | PCT ↓ <60% in 72 h | 154 | 45 (29.2) | Severe sepsis, septic shock | 60 | 67 |
| Schuetz (Validation cohort)[33b] | 2013 | USA | Prospective | ICU | ICU mortality | VIDAS | PCT ↓ <60% in 72 h | 102 | 18 (17.6) | Severe sepsis, septic shock | 78 | 61 |
| Mat Nor[34] | 2014 | Malaysia | Prospective | ICU | In hospital mortality | KRYPTOR-PCT | PCT ↓ <30% in 48 h | 67 | 27 (40.3) | Severe sepsis | 74.1 | 55 |
| Gracia de Guadiana-Romualdo[35] | 2015 | Spain | Prospective | ICU | In hospital mortality | Cobas PCT | PCT ↓ <40% in 48 h | 100 | 28 (28) | Severe sepsis and septic shock | 64.3 | 62.5 |
| Poddar[36] | 2015 | India | Prospective | ICU | 28 day mortality | Cobas PCT | PCT ↓ <50% in 4 days | 171 | 80 (46.7) | Severe sepsis, septic shock | 68 | 64 |
| Schuetz (Intention to diagnose population)[37a] | 2017 | USA | Prospective | ICU | 28 day mortality | KRYPTOR-PCT | PCT ↓ <80% in 4 days | 646 | 107 (16.5) | Severe sepsis, septic shock | 77.3 | 38.8 |
| Schuetz (Subpopulation with ICU care on day 4)[37b] | 2017 | USA | Prospective | ICU | 28 day mortality | KRYPTOR-PCT | PCT ↓ <80% in 4 days | 276 | 73 (26.4) | Severe sepsis, septic shock | 79.2 | 32.1 |
PCT: Procalcitonin, ICU: Intensive Care Unit, SICU: Surgical intensive care unit, CI: Confidence Interval, SEN: Sensitivity, SPE: Specificity
Figure 1Forest plot showing the area under curve (95% CI) of the studies to detect procalcitonin non-clearance as a predictor of mortality
Figure 2Funnel plot showing the area under curve of the different studies with their corresponding standard error
Figure 3Forest plot showing proportion of mortality in patients with procalcitonin non-clearance
Figure 4Funnel plot showing proportion of mortality in PCT non-clearance patients of different studies with their corresponding standard error